Cytori CEO Chris Calhoun presents as part of the "Cardiovascular, AMI & PAD" panel on the Regenerative Medicine Insight Track at the Biotech Showcase on January 10, 2012
BioNIR/EluNIR eDES: 1 Year Outcomes of BIONICS and NIREUS studiesMedinol Ltd
Dr. David Kandzari's overview of the 1 year outcomes of the BIONICS and NIREUS pivotal & randomized studies of the EluNIR elastomer DES by Medinol (formerly BioNIR). Presented during TCT 2016
Estudio presentado por el Dr. Andre Lamy en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
BioNIR/EluNIR eDES: 1 Year Outcomes of BIONICS and NIREUS studiesMedinol Ltd
Dr. David Kandzari's overview of the 1 year outcomes of the BIONICS and NIREUS pivotal & randomized studies of the EluNIR elastomer DES by Medinol (formerly BioNIR). Presented during TCT 2016
Estudio presentado por el Dr. Andre Lamy en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Dr. Alex Milstein, VP of Clinical at Cytori presents on the Acute Injury Technology Panel at the Cardiovascular Research Foundation's Conference on Cell Therapy for Cardiovascular Disease on January 25, 2012
Part of the MaRS Entrepreneurship 101 Event Series
"Hey buddy, can you spare a $100 million?"
OR: How to convince successful financiers to give you millions of dollars in a project doomed to fail!
Speaker: Mike Polonsky, Senior Vice President, The Equicom Group
Download the audio presentation and post questions on the MaRS blog:
http://blog.marsdd.com/2007/04/11/entrepreneurship-101-who-should-pitch/
A presentation built by Clay Marsh, MD. executive director of the OSU Center for Personalized Medicine, designed to explain some of the scientific and social angles that are a part of personalized health care.
Dr. Alex Milstein, VP of Clinical at Cytori presents on the Acute Injury Technology Panel at the Cardiovascular Research Foundation's Conference on Cell Therapy for Cardiovascular Disease on January 25, 2012
Part of the MaRS Entrepreneurship 101 Event Series
"Hey buddy, can you spare a $100 million?"
OR: How to convince successful financiers to give you millions of dollars in a project doomed to fail!
Speaker: Mike Polonsky, Senior Vice President, The Equicom Group
Download the audio presentation and post questions on the MaRS blog:
http://blog.marsdd.com/2007/04/11/entrepreneurship-101-who-should-pitch/
A presentation built by Clay Marsh, MD. executive director of the OSU Center for Personalized Medicine, designed to explain some of the scientific and social angles that are a part of personalized health care.
LOROS - Clinical Ability of Cancer Clinicians to Detect Depression (Aug09)Alex J Mitchell
This is a talk from 18-Aug-09 about how well do cancer clinicians (oncologists and clinical nurse specialists) detect depression and distress in clinical practice
CYTX 6th International Conference on Cell Therapy for Cardiovascular Disease ...Cytori Therapeutics, Inc.
Presented by Brad Conlan, Director of Regenerative Medicine on Thursday, January 20 at a Product Development Panel at the 6th International Conference on Cell Therapy for Cardiovascular Disease
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
4. The Cost of CVD
• 37% of Americans have some form of CVD
• 32 % of all deaths world-wide
• Direct cost $272 B = 17% of health care cost
• Projected to triple to $818 B by 2030
7. Life Style Regenerative
HHS : Medicine
Million Hearts AMI
Devices Heart Failure
Drugs
D e a t h
8. Patient’s cells at Point-of-Care
3. Patient’s own cells
in about one hour
2. Point Of Care
Tissue Processing Device
removes adipocytes
1. Small volume
Liposuction
9. Relevance of Heart Damage
% Left Ventricle infarct size 40%
% of patients
35% in heart failure or death
2 years after AMI
30%
25% 46% of patients
20%
15%
7% of patients
10%
10. Acute Heart Attack
APOLLO TRIAL
• Prospective European Multicenter Trial
• Randomized (3:1)
• Double Blind
• Placebo controlled
• Blinded independent core labs
• Safety & Feasibility Trial
• n = 14 (4 placebo, 10 treated)
Eric Duckers, MD, PhD
Rotterdam, The Netherlands
11. Change in Infarct Size
% Left Ventricle infarct size 40% Standard of Care
35%
30%
Significantly Higher
25% 25% 25%
Rate of MACE
20%
15% Significantly Lower
Rate of MACE
10%
Baseline 6 Months
12. Cell Treated reduced damage by 50%
ADRC’s
% Left Ventricle infarct size 40% Standard of Care
35%
32%
30%
Significantly Higher
25% 25% 25%
Rate of MACE
20%
15% Significantly Lower
15%
Rate of MACE
10%
Baseline 6 Months
13. Change in Infarct Size
Persistent to 18 Months
change in rel. infarct size (I/LV) (matched pairs)
all pts baseline 6 mo
control
Tx
24,7% 24,7%
ADRC
Tx
31,6% 15,4%
Data provided by:
Eric Duckers, MD, PhD
14. Standard of Care Patients
Progressing into Heart Failure
24,4 cc
improvement
(-72,2%)
Data provided by:
Eric Duckers, MD, PhD
Change in ESV
ESV was markedly reduced in ADRC patients as compared to placebo control patients
(as measured by 2D TTE, cMRI and SPECT, PTE)
15. Cell Treated Patients
Not Progressing into Heart Failure
24,4 cc
improvement
(-72,2%)
Data provided by:
Eric Duckers, MD, PhD
Change in ESV
ESV was markedly reduced in ADRC patients as compared to placebo control patients
(as measured by 2D TTE, cMRI and SPECT, PTE)
16. Cell Treated Patients
Better Perfusion of the Heart
MIBI SPECT TSS change (matched pairs)
+867% +800%
improvement improvement
Data provided by:
Eric Duckers, MD, PhD
Perfusion defect in LAD territory:
Reduction in perfusion defect in patients treated with ADRC compared to placebo
patients (9,7-fold improvement in LAD perfusion territory) as analyzed by MIBI SPECT (TSS scores)
17. Cell Treated Patients
Experienced Fewer Arrhythmias
Lower abnormal ventricular beat rate in cell group
More significant Ventricular Arrhythmias in
placebo
Higher frequency of recordings with Ventricular
Premature Beats (VPB) in Controls
Higher number of VPBs per recording in placebo
Data provided by:
Eric Duckers, MD, PhD
18. Apollo Summary
ADRCs are safe in the treatment of STEMI
No safety concerns
No new Major Adverse Cardiac Events
No Deaths
Efficacy
Concordant improvement in infarct and ischemia
Mean reduction in Infarct Size is maintained to 18 months
Improvement in cardiac perfusion is maintained to 18 months
Long-term data indicates slowing progression toward heart failure
Positive impact on arrhythmia in cell-treatment patents
Apollo data consistent with pre-clinical data
19. Acute Heart Attack
ADVANCE TRIAL
• European Pivotal Trial
• Prospective
• Randomized (2:2:1)
• Double Blind
• Placebo controlled
• Blinded independent core labs
• Up to 370 patients for STEMI
• Currently enrolling & treating
Eric Duckers, MD, PhD
Rotterdam, The Netherlands
20. Advance EU AMI Trial
• 30 – 35 sites to treat up to 360 patients
• ~60 sites identified & interested; ½ in G-5
• 23 sites selected & committed
• Various states of regulatory process
• Focus in 2012 to bringing sites online: 30 by YE
• Enrollment goal: 1 pt / site / month
21. Advance EU AMI Trial
ADVANCE is a European approval trial
22. Acute Myocardial Infarction
Estimated Market Size for AMI Patients in Europe
Annual Heart Attack Incidence (EU) 1.9 million
% STEMI (large heart attacks) 38%
Target Addressable Procedures 720,000
Estimated Price per Treatment $ 10,000
EU AMI Market
$ 7.2 Billion
23. Acute Myocardial Infarction
Annual STEMI Heart Attack Incidence (EU) 720,000
Progression to Heart Failure in 24 months (46%) 330,000
Total Annual Cost For New HF patients ($180k / yr) $ 60 Billion
Est. Progression to HF in 24 mo w Cell Tx (7%) 50,000
Total Annual Cost for New HF patients (180k / yr) $ 9 Billion
EU HF Cost Savings
$ 51 Billion
Savings would compound over future years
25. Standard of Care Patients
Key Heart Function Continued Decline
20.0
Standard of Care
19.0
18.0
% MVO2
16.0
15.5 15.3
14.0 Transplant List
Baseline 6 Mos 18 Mos
Change in Mass Volume of Oxygen (MV02) from Baseline to 6 & 18 months
26. Cell Treated Patients
Improved in Key Heart Function
20.0 ADRC’s
Standard of Care
19.0
P<0.05 P<0.05
18.0
% MVO2
17.2 17.1
16.0 16.6
15.5 15.3
14.0 Transplant List
Baseline 6 Mos 18 Mos
Change in Mass Volume of Oxygen (MV02) from Baseline to 6 & 18 months
27. Chronic Myocardial Ischemia
28 Month Mortality Rate
Safe & Feasible
• Harvest procedure (Liposuction) safe
• Cell delivery safe Treated
MVO2: significant change at 6 & 18 months Placebo
• MVO2 correlates to improved survival
• MVO2 ≤ 14 = 47% 1 yr survival rate
0% 10% 20% 30% 40%
METS: significant change at 6 & 18 months
Infarct size: 8.2% change at 6 months Next Steps:
Lower cardiac mortality rate:
Applying for European Approval
• At avg. follow up of 28 months:
- 2/6 placebo Initiating US IDE Clinical Trial: ATHENA
- 1/21 treated
28. “No Option” Heart Failure
Estimated Market Size for No Option Patients in Europe
Region # of Patients (Incidence) # of Patients (10-Yr Prevalence)
United Kingdom 40,000 400,000
Italy 40,000 400,000
Germany 55,000 550,000
France 40,000 400,000
Spain 30,000 300,000
Total G5 205,000 2,050,000
G5 Market * Estimated price per treatment: $ 10,000
$ 20 Billion*
29. 38 Worldwide Issued Patents; > 100 pending
Devices Devices Cosmetic & Reconstructive Cardiovascular Therapies Pipeline Therapies
Current Next Generation Surgery (CRS)
US: (5) US: (1) US: (4) Europe: (1) US: (2)
CELUTION DEVICE (‘484) CELUTION FUTURE CELUTION FOR MIXING ADRCS PLUS ADRCS FOR CARDIAC (‘382) CELUTION FOR BONE
CELUTION DEVICE PLUS ADDITIVES GENERATIONS (‘075) FAT (‘488) (‘043)
(‘420) CELUTION OR NEXT GEN DEVICES FOR Australia: (1) CELUTION OUTPUT PLUS
STEMSOURCE DEVICE (‘115) India: (1) SOFT TISSUE DEFECTS (‘684) CELUTION FOR CARDIOVASCULAR PROSTHETIC
CELUTION DEVICE PLUS SENSORS FOR CELUTION FUTURE ADRCS PLUS FAT PLUS ADDITIVES (‘858) FOR BONE RELATED
CLINICALLY SAFE OUTPUT (‘670) GENERATIONS (‘529) (‘795) DISORDERS (‘716)
BEDSIDE COMPREHENSIVE ADRCS PLUS FAT (‘672) Singapore: (1)
DEVICE (‘059) Australia: (1) CELUTION FOR CARDIOVASCULAR Europe: (2)
CELUTION WITH CENTRIFUGE Japan: (1) (‘590) CELUTION FOR ACUTE
Japan: (2) OR CELUTION AND NEXT GEN DEVICES TUBULAR NECROSIS (‘834)
CELUTION DEVICE (‘952) FILTER (‘937) FOR MIXING ADRCS PLUS FAT (‘041) China: (1) ADRCS FOR WOUND
CELUTION FOR CLINICALLY SAFE CELUTION FOR HEALING (‘833)
OUTPUT (‘556) Singapore: (1) CARDIOVASCULAR (‘104)
CELUTION & FUTURE Japan: (1)
Korea: (3) GENERATIONS (‘683) Russia: (1) ADRCS FOR WOUND
CELUTION DEVICE (‘995) CELUTION FOR CARDIOVASCULAR HEALING (‘699)
STEMSOURCE DEVICE (‘812) Israel: (1) (‘924)
CELUTION DEVICE (‘139) CELUTION WITH CENTRIFUGE India: (1)
OR South Africa: (1) ADRCS FOR WOUND
India: (1) FILTER (‘800) CELUTION FOR CARDIOVASCULAR HEALING (‘580)
CELUTION DEVICE (‘706) (‘446)
Mexico: (1)
Australia: (1) CELUTION FUTURE Mexico: (1)
CELUTION DEVICE (‘135) GENERATIONS CELUTION FOR CARDIOVASCULAR
STEMSOURCE DEVICE (‘901) (‘775)
China: (1)
CELUTION DEVICE (‘689)
30. Summary
• CVD represents a $80+ billion market opportunity
• Regenerative Medicine is needed to improve
treatment options & outcomes
• Cell therapy using the Celution System has shown
significant benefit in both acute & chronic heart
• First approval for CMI anticipated in 2012